Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib + Fulvestrant vs CDK4/6i + Fulvestrant in HR+/HER2- Breast Cancer
NCT07666555Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of culmerciclib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07666555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07666555.